Engene appoints lee giguere as chief legal officer and corporate secretary

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support engene during late-stage clinical development and anticipated future commercial launch of its lead program eg-70 boston and montreal , jan. 30, 2024 /prnewswire/ - engene holdings inc. ("engene," (nasdaq: engn), a clinical-stage genetic medicines company whose lead program is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced the appointment of lee giguere as chief legal officer and corporate secretary. "i am delighted to welcome lee, an experienced public biotech legal executive, to engene as we advance the development of eg-70 in our ongoing pivotal-stage legend study in bcg-unresponsive non-muscle invasive bladder cancer," said jason d.
ENGN Ratings Summary
ENGN Quant Ranking